Werth et al. Lenabasum phase 3 trial indermatomyositis. Primary endpoint (TIS week 28) not met. Subgroup analysis suggest small effect on muscle and modest effect on skin disease @rheumnow #ACR22 Abstr#0173 https://t.co/qhL2PcTcHV https://t.co/uR8Bg5awiK
Links:
Cutaneous Manifestations, Clinical Trials, Safety Efficacy and Safety of Lenaba…
https://acrabstracts.org/abstract/cutaneous-manifestations-clinical-trials-safe…
12-11-2022
